Examining Aztreonam-Avibactam for Gram-Negative Infections

A novel pairing of aztreonam and avibactam offers a long-needed solution to combat highly drug-resistant gram-negative bacteria, particularly those producing difficult-to-treat metallo-β-lactamases.

Joshua Rosenberg, MD, discuses the differences in clinical trials that enroll both intra-abdominal infection patients and those with hospital- or ventilator-associated pneumonia face major complexity because these two groups differ widely in baseline severity, mortality risk, and expected treatment outcomes